Phenotype Dosage Sensitivity Model for Autism Genetic Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The phenotypic heterogeneity in autism spectrum disorders (ASD) is not well understood, particularly in simplex families with severe de novo mutations, where the genetic architecture is less complex, yet phenotypic variations are as diverse as in more general ASD cohorts, making it challenging to diagnose and treat effectively.
Innovation Solution
The introduction of a new genetic parameter to quantify the relationship between changes in gene dosage and specific autism phenotypes, using sequencing and microarray techniques to analyze likely gene-disrupting mutations, and applying regression models to explain phenotypic heterogeneity, along with personalized treatment approaches based on gene expression dosage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If de novo mutations are identified in simplex families with ASD, then genetic architecture becomes less complex, but phenotypic heterogeneity remains as diverse as general ASD cohorts
Solution Approach 1:
The patent introduces a new genetic parameter called 'phenotype dosage sensitivity' that quantifies the relationship between gene dosage changes and specific autism phenotypes. This parameter enables the classification of genes based on their sensitivity to dosage variations, thereby explaining phenotypic heterogeneity through a new dimensional parameter rather than through genetic complexity alone.
Solution Approach 2:
The patent employs regression models as intermediary tools that connect gene dosage information with phenotypic outcomes. These models serve as mediators that translate genetic data into predictive phenotypic information, enabling personalized treatment strategies without requiring direct interpretation of complex gene-phenotype relationships.
2Loss of information
If regression models are used to explain phenotypic heterogeneity, then understanding of etiology improves, but personalization of treatment requires additional gene expression analysis
Solution Approach 1:
The patent performs preliminary classification of genes into different phenotype dosage sensitivity categories using regression models. This preliminary action organizes genetic information in advance, creating a structured framework that simplifies subsequent treatment personalization by pre-establishing which genes are most sensitive to dosage changes and likely to respond to therapeutic interventions.
Data Source
AI summary
It was discovered that, for individuals with certain types of mutations, clinical outcomes or phenotypes can be very accurately predicted. For example, for an individual with autism harboring a de novo LGD mutation, the patient’s IQ, behavioral phenotypes, and motor/movement phenotypes, and the severity of autism can be predicted. For these LGD mutations, due to a mRNA surveillance mechanism called NMD (nonsense-mediated decay), it was discovered that clinical outcomes and phenotypes are strongly correlated with the expression intensity of the exon harboring the mutation. A method/model was developed, which is called PDS (phenotype dosage sensitivity), to predict phenotypes based on this observation, and the model is able to predict phenotypes at a much higher level of accuracy not previously possible. This disclosure is the first to link LGD mutations and clinical phenotypes in this manner.